Media Coverage

The partnership between SphingoTec and Beckman Coulter will bring the innovative penKid assay to Beckman Coulter's Access Family of Immunoassay Analyzers, offering early detection of kidney function decline in critical care settings and potentially impacting the care of 13 million patients affected by acute kidney injury annually worldwide.

By developing a fully automated penKid diagnostic test, Beckman Coulter and SphingoTec are advancing a more precise and early detection method for acute kidney injury that overcomes traditional biomarker limitations, offering critical care physicians a more reliable tool for timely patient intervention.

Beckman Coulter Diagnostics and SphingoTec have partnered to develop a fully automated high-throughput penKid assay for Beckman Coulter's Access immunoassay analyzers, aiming to improve acute kidney injury diagnosis and management in central laboratories worldwide.

SphingoTec's licensing deal with Beckman Coulter for its penKid assay marks a significant milestone, enabling US market expansion and global reach through Beckman's extensive immunoassay platform network, while addressing the critical need for early detection of acute kidney injury in intensive care settings.

SphingoTec secures €5M in Series C funding to accelerate out-licensing of innovative critical care biomarkers penKid and bio-ADM, expand globally including US market entry, and advance towards profitability with support from Think.Health Ventures and existing investors.

SphingoTec secures €5M Series C funding to expand globally, including US market entry, and advance commercialization of its innovative biomarker-based diagnostics for critical care.

At the Vicenza Course, Prof. Ronco and Deborah Bergmann, CEO of Sphingotec, are discussing about the new developments of the new biomarker penKid

Verbesserte Nierenfunktionsbewertung durch einen innovativen Nierenfunktions-Biomarker: Eine präzise Beurteilung der Nierenfunktion ist von entscheidender Bedeutung in der modernen Intensivmedizin und spielt eine wesentliche Rolle bei der frühen Diagnose von Krankheiten und Komplikationen sowie einer personalisierten Th erapieplanung.

Es sind winzige Moleküle im menschlichen Blut, die zeigen, dass Lebensgefahr besteht – in Echtzeit. Sphingotec hat zwei neue Biomarker identifiziert und bietet Medizinern die Chance, rechtzeitig lebensrettende Maßnahmen zu ergreifen, um ein komplettes Organversagen oder eine Nierendysfunktion zu verhindern.

Berlin ist die Gesundheitshauptstadt Deutschlands. Das spiegelt sich in der prosperierenden Medtech-Start-up-Szene wider. Die Protagonisten der neuen Generation junger Unternehmen gehen vermehrt den körpereigenen Prozessen auf die Spur – damit die Menschen lange leben.

Bei der SphingoTec GmbH in Hennigsdorf bei Berlin wurde das Management erneuert: Der Geschäftsführung gehören nun Deborah Bergmann (CEO) und Dr. Florian Uhle (CMO) an. Nicole Witzmann übernahm die Position des Finanzvorstands.

SphingoTec GmbH has introduced an improved formula for estimating Glomerular Filtration Rate (GFR) using its kidney function biomarker, penKid. Their data indicates a strong correlation between penKid and measured GFR (mGFR), surpassing the performance of commonly used GFR estimation equations.

Point-of-care test developer Boditech Med and biomarker developer SphingoTec announced that they entered a commercialization agreement for a point-of-care blood test to assess kidney function and acute kidney injury.

The Thematic Series share thoughts based on scientific data and help the clinician to individualize the different aspects of the patient management. They list the following paper: Evaluation of Proenkephalin A 119–159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury

SphingoTec GmbH has received its IVDR certificate for its sphingotest® penKid® confirming the quality and compliance of this product with regulatory requirements.

The mission of the company SphingoTec is to improve patient care through innovative diagnostic solutions for acute and intensive care medicine.

Boditech Med will develop and make point-of-care tests for acute kidney injury using a kidney function biomarker licensed from SphingoTec.

Acute kidney injury (AKI) is a life-threatening disease that has no obvious symptoms in the early stages. Early identification of patients with AKI is one of the most critical unmet needs of physicians in their daily clinical practice. The focus of this article is on functional kidney biomarkers since it is not possible for damage markers to estimate the glomerular filtration rate (GFR).

International medical leaders discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients.

During the 4th Scientific Symposium held near Potsdam, Germany, international medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients.

Find out why Dr. Rainer Strohmenger from Wellington Partners is convinced that innovations from Henningsdorf are significantly enriching the German life science industry.

A multi-center study led by the University Hospital Hamburg-Eppendorf (UKE) is evaluating one of the first personalized approaches for moderate to severe COVID-19 patients.

Biomarker-guided trial led by University Hospital Hamburg-Eppendorf (UKE) opens new avenues for personalized medicine for the treatment of COVID-19.

Serial entrepreneur and industry expert Dr. Andreas Bergmann explains his diagnostic strategy in an interview.

Learn more about three major sepsis pathways and how to improve patients outcomes and clinical decisions in the Technology Networks Article by Dr. Karolina Szczesna.

In a Private Wealth cover story, Dr. Andreas Bergmann shares his vision and progress towards developing new diagnostics and drugs for diseases that are recognized as global health burdens, such as sepsis.

Innovations made in Germany: We are excited to be featured in this Deutsche Welle coverage as healthcare innovators, alongside Biontech and other pioneers of the complex biotech scenery.

New tool for critical care: read about the clinical relevance of DPP3 and its potential role in the management of septic patients.

A BioWorld article looks at personalized sepsis management: SphingoTec's biomarkers could help to determine the best treatment for critically ill patients. Read the full article for more details.

Acute Kidney Injury is affecting 1 in 3 Intensive Care Unit (ICU) patients and the current standard of care diagnostics has considerable sensitivity and specificity limitations, there is an urgent need to implement new biomarkers to assist a better management of AKI.

The latest consensus meeting of international experts in critical care and nephrology supports the use of novel biomarkers in the prevention and management of Acute Kidney Injury (AKI). Read more in the following article.

Die Uniklinik RWTH Aachen und die SphingoTec GmbH („SphingoTec“) gaben heute bekannt, dass sie ihre Zusammenarbeit mit der Implementierung der neuen Biomarker in der klinischen Routine weiter ausgebaut haben.

penKid is an established biomarker for detecting AKI in adults. The current study shows that reference values for penKid in children are much higher than in adults. Read more here.

Diagnostics company SphingoTec GmbH announced the launch of its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).

SphingoTec launched IB10 Sphingotest bio-ADM, a CE IVD-marked point-of-care test to quantitatively determine blood levels of bioactive adrenomedullin.

Diagnostics company SphingoTec GmbH ("SphingoTec") today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM®).

Experts representing European medical centers agreed that novel biomarkers are required for triaging and monitoring of these patients to optimally make use of the available medical resources and improve outcomes.

High blood levels of Dipeptidyl Peptidase 3 (DPP3) indicate the upcoming multiple organ failure and death in burn patients, as announced by the Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH.

The publication of new data shows that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risks in burn patients.

High blood concentrations of the biomarker DPP3, previously described as an indicator of massive cell death and inflammation, has been shown to be associated with organ failure fatal outcomes in patients with severe burns.

Sepsis is a potentially life-threatening condition caused by the body's response to an infection. The body normally releases chemicals into the bloodstream to fight infection. Read more here.

Proenkephalin (PENK) is a novel candidate biomarker for kidney function that is filtrated in the glomerulus, shown to represent steady-state GFR in patients with different severities of renal insufficiency and is reliably predictive for acute kidney injury in patients with severe burns.

Bioactive Adrenomedullin is a biomarker for endothelial dysfunction and allows the prediction of septic shock as elevated blood levels of bio-ADM® predict blood pressure break down and blood vessel leakage resulting in edema

Diagnostics company SphingoTec GmbH have announced the launch of its IB10 sphingotest® penKid®, a CE-IVD-marked point-of-care test for Proenkephalin (penKid®), the biomarker that allows real-time assessment of kidney function with a simple blood test. Read the full article here.

Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland. Read more in the press release.

SphingoTec's kidney function biomarker penKid® was found to accurately detect acute kidney injury (AKI) in infants.